RCM
ARTV

Revelation Capital Management’s Artiva Biotherapeutics ARTV Stock Holding History

Revelation Capital Management’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.9M Hold
299,311
– – 2.65% 2
2026
Q1 		$1.93M Hold
299,311
– – 2.86% 2
2025
Q4 		$1.28M Buy
+299,311
New +$1.13M 1.54% 2

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Revelation Capital Management's ARTV Position: Q2 2026 in Review

Revelation Capital Management held its Artiva Biotherapeutics (ARTV) position steady in Q2 2026 at 299,311 shares worth $2.9M. The position accounts for 2.65% of the portfolio, ranked #2.

Revelation Capital Management first reported a position in ARTV in Q4 2025 and has held it in 3 quarters since. 72 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

  • Revelation Capital Management held 299,311 shares of Artiva Biotherapeutics worth $2.9M as of Q2 2026.
  • Revelation Capital Management left its Artiva Biotherapeutics share count unchanged in Q2 2026.
  • Artiva Biotherapeutics made up 2.65% of Revelation Capital Management's portfolio in Q2 2026, its #2 holding.
  • Revelation Capital Management first reported a position in Artiva Biotherapeutics in Q4 2025 and has held it in 3 quarters since.
  • 72 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on Revelation Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.